Oculis Holding AG (OCS)

Currency in USD
16.130
-0.220(-1.35%)
Closed·
16.1300.000(0.00%)
·
OCS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
OCS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.07516.370
52 wk Range
11.56023.080
Key Statistics
Prev. Close
16.35
Open
16.37
Day's Range
16.075-16.37
52 wk Range
11.56-23.08
Volume
10.42K
Average Volume (3m)
17.69K
1-Year Change
33.86%
Book Value / Share
3.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OCS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.598
Upside
+133.10%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Oculis Holding AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Oculis Holding AG Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Compare OCS to Peers and Sector

Metrics to compare
OCS
Peers
Sector
Relationship
P/E Ratio
−6.3x−1.0x−0.5x
PEG Ratio
0.210.000.00
Price/Book
4.7x0.7x2.6x
Price / LTM Sales
884.1x1.8x3.3x
Upside (Analyst Target)
119.1%155.6%38.9%
Fair Value Upside
Unlock16.2%5.4%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.598
(+133.10% Upside)

Earnings

Latest Release
Aug 21, 2025
EPS / Forecast
-0.49 / -0.46
Revenue / Forecast
261.00K / 960.00K
EPS Revisions
Last 90 days

OCS Income Statement

People Also Watch

190.81
IQV
+1.10%
29.96
RARE
-1.12%
27.680
LQDA
+0.80%
24.050
NAMS
+0.42%
8.07
ALVO
+0.25%

FAQ

What Stock Exchange Does Oculis Holding Trade On?

Oculis Holding is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Oculis Holding?

The stock symbol for Oculis Holding is "OCS."

What Is the Oculis Holding Market Cap?

As of today, Oculis Holding market cap is 844.18M.

What Is Oculis Holding's Earnings Per Share (TTM)?

The Oculis Holding EPS (TTM) is -2.32.

From a Technical Analysis Perspective, Is OCS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Oculis Holding Stock Split?

Oculis Holding has split 0 times.

How Many Employees Does Oculis Holding Have?

Oculis Holding has 49 employees.

What is the current trading status of Oculis Holding (OCS)?

As of 30 Aug 2025, Oculis Holding (OCS) is trading at a price of 16.130, with a previous close of 16.35. The stock has fluctuated within a day range of 16.075 to 16.370, while its 52-week range spans from 11.560 to 23.080.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.